The European Commission has approved Stada/Alvotech’s Uzpruvo (ustekinumab), the EU’s first biosimilar version of Janssen’s originator drug Stelara, for the treatment of Crohn’s disease, psoriasis and psoriatic arthritis.
The EU marketing authorization (MA) “paves the way for market entry as soon as possible” following the July 2024 expiry of a supplementary protection
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?